AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris
April 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday for allegedly misusing its patents to extend its monopoly on its blockbuster blood-disease drug Soliris.
Health plan EmblemHealth said in the proposed class action lawsuit, opens new tab that Alexion wrongly obtained new patents to block biosimilar versions of Soliris for four years after its patents on the drug should have expired.
EmblemHealth said the alleged scheme violated U.S. antitrust law and could cause overpayments of more than $2 billion for Soliris.
Spokespeople for AstraZeneca did not immediately respond to a request for comment on the complaint.
"We are concerned about practices that shut down competition and increase drug costs. That's what this litigation is about," an EmblemHealth spokesperson said.
EmblemHealth is seeking to represent a class of U.S. Soliris buyers in the lawsuit.
Soliris is used to treat rare blood disorders. AstraZeneca earned more than $1.4 billion from sales of the drug in the first half of 2024, according to a company report.
EmblemHealth said in the lawsuit that AstraZeneca charges "one of the single highest drug costs in U.S. history" for Soliris, which costs "upwards of $500,000 per patient per year."
AstraZeneca's patents covering Soliris should have expired in 2021, but the company misled the U.S. Patent and Trademark Office to obtain more patents with expiration dates "well into the future," according to the complaint. The lawsuit said AstraZeneca used the new patents to "extract settlements" from competitors and delay their biosimilars until March 2025 at the earliest.
EmblemHealth asked the court for an order ending AstraZeneca's monopoly on Soliris and an unspecified amount of monetary damages.
The case is EmblemHealth Inc v. Alexion Pharmaceuticals Inc, U.S. District Court for the District of Massachusetts, No. 1:25-cv-10985.
For EmblemHealth: Thomas Sobol and Gregory Arnold of Hagens Berman Sobol Shapiro; and Mark Fischer and Rob Griffith of Rawlings & Associates
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
5 hours ago
- Reuters
China puts six-month limit on its ease of rare-earth export licenses, WSJ reports
June 11 (Reuters) - China is putting a six-month limit on rare-earth export licenses for U.S. automakers and manufacturers, The Wall Street Journal reported on Wednesday citing people familiar with the matter.
Reuters
6 hours ago
- Reuters
IMF, Serbia reach staff-level agreement on 36-month deal
BELGRADE, June 11 (Reuters) - The International Monetary Fund (IMF) and Serbia have reached staff-level agreement on the first review under a 36-month arrangement to help support economic reforms, the fund said in a statement on Wednesday. The so-called Policy Coordination Instrument (PCI) was signed in October to make it easier for the Balkan country to secure lending from other sources. Under the arrangement, Serbian authorities are committed to a fiscal deficit limit of 3% of gross domestic product over three years. The review will be subject to approval by the IMF Executive Board, the fund said in the statement which was issued after its two-week trip to Serbia. It also warned that downside risks for the economy were elevated. The IMF said political tensions over anti-government protests and blockades of state universities launched last November "may weigh on confidence". Serbia has seen months of anti-government rallies after 16 deaths from a railway station roof collapse triggered accusations of widespread corruption and negligence. The IMF warned that a global growth slowdown and increasing "geoeconomic fragmentation could negatively affect exports and foreign direct investment". However, it expects Serbia's economy to grow 3% this year and 4% in 2026. "Serbia has built up substantial buffers to respond to shocks — foreign exchange reserves and government deposits are high, public debt is declining, and banks are well-capitalised and liquid," the IMF said.
Reuters
6 hours ago
- Reuters
Lutnick says US tariff levels on China won't change
June 11 (Reuters) - U.S. Commerce Secretary Howard Lutnick said on Wednesday that the 55% tariffs imposed by the United States on China will not change after a trade deal was struck between the two countries. A U.S.-China trade deal is "done," U.S. President Donald Trump said earlier in the day, hours after negotiators from Washington and Beijing agreed on a framework to get a fragile trade truce back on track. "You can definitely say that," Lutnick told CNBC in an interview when asked if the tariff levels on China would not change. The trade deal, which needs to signed by both Trump and Chinese President Xi Jinping, would remove Chinese export restrictions on rare earth minerals and other critical industrial components. Lutnick also said China has agreed to examine how it can do more business with the U.S. He said that trade deals with other countries can be expected starting next week.
